<?xml version='1.0' encoding='utf-8'?>
<document id="29788670"><sentence text="Personalized medicine for eradication of Helicobacter pylori." /><sentence text="Regimens for eradication of Helicobacter pylori consist of a proton-pump inhibitor (PPI) and one or two antimicrobial agents, such as amoxicillin, clarithromycin or metronidazole"><entity charOffset="134-145" id="DDI-PubMed.29788670.s2.e0" text="amoxicillin" /><entity charOffset="147-161" id="DDI-PubMed.29788670.s2.e1" text="clarithromycin" /><entity charOffset="165-178" id="DDI-PubMed.29788670.s2.e2" text="metronidazole" /><pair ddi="false" e1="DDI-PubMed.29788670.s2.e0" e2="DDI-PubMed.29788670.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29788670.s2.e0" e2="DDI-PubMed.29788670.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29788670.s2.e0" e2="DDI-PubMed.29788670.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29788670.s2.e1" e2="DDI-PubMed.29788670.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29788670.s2.e1" e2="DDI-PubMed.29788670.s2.e2" /></sentence><sentence text=" As the pharmacokinetics and pharmacodynamics of PPIs are affected by polymorphism of CYP2C19, doses and dosing schemes of a PPI should be optimized based on genotype status of each patient in order to yield higher eradication rates" /><sentence text=" PPIs affect the pharmacokinetics of other substrates of CYP2C19, such as warfarin and diazepam"><entity charOffset="74-82" id="DDI-PubMed.29788670.s4.e0" text="warfarin" /><entity charOffset="87-95" id="DDI-PubMed.29788670.s4.e1" text="diazepam" /><pair ddi="false" e1="DDI-PubMed.29788670.s4.e0" e2="DDI-PubMed.29788670.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29788670.s4.e0" e2="DDI-PubMed.29788670.s4.e1" /></sentence><sentence text=" Acid inhibition induced by a PPI also affects the pharmacokinetics of some drugs, such as itraconazole"><entity charOffset="91-103" id="DDI-PubMed.29788670.s5.e0" text="itraconazole" /></sentence><sentence text=" Clarithromycin, one of the most frequently used antimicrobial agents in eradication of H"><entity charOffset="1-15" id="DDI-PubMed.29788670.s6.e0" text="Clarithromycin" /></sentence><sentence text=" pylori, inhibits activity of CYP3A4, meaning that the pharmacokinetics of substrates of CYP3A4 are affected by clarithromycin"><entity charOffset="112-126" id="DDI-PubMed.29788670.s7.e0" text="clarithromycin" /></sentence><sentence text=" Therefore, clinicians must pay attention to the other drugs dosed to each of their patients" /><sentence text=" Therefore, the eradication regimen for H" /><sentence text=" pylori infection should be designed with the CYP2C19 genotype status, bacterial susceptibility to antimicrobial agents, and other drugs being taken by each patient having been taken into consideration" /><sentence text="" /></document>